B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613

Benzinga Newsdesk www.benzinga.com Negative 88.5%

Neg 88.5% Neu 0% Pos 0%

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.